BeiGene, Ltd. (United States)

BeiGene is a global biotechnology company focused on developing innovative cancer treatments. The company’s oncology portfolio includes Brukinsa (zanubrutinib), a BTK inhibitor for various blood cancers including mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia. BeiGene also develops Tislelizumab, a PD-1 inhibitor for solid tumors and hematological malignancies. The company combines global research capabilities with extensive clinical development expertise.